Gregg E.W. Li Y. Wang J. Burrows N.R. Ali M.K. Rolka D. Williams D.E. Geiss L.

Changes in diabetes-related complications in the United States, 1990-2010.

N Engl J Med. 370: 1514-1523

Update on Diabetic Nephropathy: Core Curriculum 2018.

Am J Kidney Dis. 71: 884-895

Effects of Intermittent Fasting on Health, Aging, and Disease.

N Engl J Med. 381: 2541-2551Sutton E.F. Beyl R. Early K.S. Cefalu W.T. Ravussin E. Peterson C.M.

Early Time-Restricted Feeding Improves Insulin Sensitivity, Blood Pressure, and Oxidative Stress Even without Weight Loss in Men with Prediabetes.

Cell Metab. 27 (): 1212-1221Ko G.J. Kalantar-Zadeh K. Goldstein-Fuchs J. Rhee C.M.

Dietary Approaches in the Management of Diabetic Patients with Kidney Disease.

Nutrients. 9Barnosky A.R. Hoddy K.K. Unterman T.G. Varady K.A.

Intermittent fasting vs daily calorie restriction for type 2 diabetes prevention: a review of human findings.

Transl Res. 164: 302-311

Fasting: molecular mechanisms and clinical applications.

Cell Metab. 19: 181-192Puchalska P. Crawford P.A.

Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics.

Cell Metab. 25: 262-284

Fuel metabolism in starvation.

Annu Rev Nutr. 26: 1-22

Fueling Performance: Ketones Enter the Mix.

Cell Metab. 24: 373-375Shimazu T. Hirschey M.D. Newman J. He W. Shirakawa K. Le Moan N. Grueter C.A. Lim H. Saunders L.R. Stevens R.D. Newgard C.B. Farese Jr., R.V. de Cabo R. Ulrich S. Akassoglou K. Verdin E.

Suppression of oxidative stress by β-hydroxybutyrate, an endogenous histone deacetylase inhibitor.

Science. 339: 211-214Edwards C. Copes N. Bradshaw P.C.

D-ß-hydroxybutyrate: an anti-aging ketone body.

Oncotarget. 6: 3477-3478Stekovic S. Hofer S.J. Tripolt N. Aon M.A. Royer P. Pein L. Stadler J.T. Pendl T. Prietl B. Url J. Schroeder S. Tadic J. Eisenberg T. Magnes C. Stumpe M. Zuegner E. Bordag N. Riedl R. Schmidt A. Kolesnik E. Verheyen N. Springer A. Madl T. Sinner F. de Cabo R. Kroemer G. Obermayer-Pietsch B. Dengjel J. Sourij H. Pieber T.R. Madeo F.

Alternate Day Fasting Improves Physiological and Molecular Markers of Aging in Healthy, Non-obese Humans.

Cell Metab. 30 (): 462-476Han Y.M. Bedarida T. Ding Y. Somba B.K. Lu Q. Wang Q. Song P. Zou M.H.

β-Hydroxybutyrate Prevents Vascular Senescence through hnRNP A1-Mediated Upregulation of Oct4.

Mol Cell. 71 (): 1064-1078Tajima T. Yoshifuji A. Matsui A. Itoh T. Uchiyama K. Kanda T. Tokuyama H. Wakino S. Itoh H.

beta-hydroxybutyrate attenuates renal ischemia-reperfusion injury through its anti-pyroptotic effects.

Kidney international. 95: 1120-1137

Torres JA, Kruger SL, Broderick C, Amarlkhagva T, Agrawal S, Dodam JR, Mrug M, Lyons LA, Weimbs T. Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease. Cell metabolism 2019; 30: 1007-1023 e1005.

Qi H. Gu L. Xu D. Liu K. Zhou M. Wang Y. Wang X. Li Y. Qi J.

β-Hydroxybutyrate inhibits cardiac microvascular collagen 4 accumulation by attenuating oxidative stress in streptozotocin-induced diabetic rats and high glucose treated cells.

Eur J Pharmacol. 899: 174012Trotta M.C. Maisto R. Guida F. Boccella S. Luongo L. Balta C. D'Amico G. Herman H. Hermenean A. Bucolo C. D'Amico M.

The activation of retinal HCA2 receptors by systemic beta-hydroxybutyrate inhibits diabetic retinal damage through reduction of endoplasmic reticulum stress and the NLRP3 inflammasome.

PLoS One. 14e0211005Patrakka J. Tryggvason K.

New insights into the role of podocytes in proteinuria.

Nat Rev Nephrol. 5: 463-468

The podocyte's response to injury: role in proteinuria and glomerulosclerosis.

Kidney Int. 69: 2131-2147White K.E. Bilous R.W. Marshall S.M. El Nahas M. Remuzzi G. Piras G. De Cosmo S. Viberti G.

Podocyte number in normotensive type 1 diabetic patients with albuminuria.

Diabetes. 51: 3083-3089Pagtalunan M.E. Miller P.L. Jumping-Eagle S. Nelson R.G. Myers B.D. Rennke H.G. Coplon N.S. Sun L. Meyer T.W.

Podocyte loss and progressive glomerular injury in type II diabetes.

J Clin Invest. 99: 342-348Palmer A.K. Tchkonia T. LeBrasseur N.K. Chini E.N. Xu M. Kirkland J.L.

Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity.

Diabetes. 64: 2289-2298Venkatachalam G. Surana U. Clément M.V.

Replication stress-induced endogenous DNA damage drives cellular senescence induced by a sub-lethal oxidative stress.

Nucleic Acids Res. 45: 10564-10582Min L.J. Mogi M. Iwai M. Horiuchi M.

Signaling mechanisms of angiotensin II in regulating vascular senescence.

Ageing Res Rev. 8: 113-121

Senescence in Health and Disease.

Cell. 169: 1000-1011

Survive or thrive: tradeoff strategy for cellular senescence.

Exp Mol Med. 49: e342Xu W. Ge Y. Liu Z. Gong R.

Glycogen synthase kinase 3beta dictates podocyte motility and focal adhesion turnover by modulating paxillin activity: implications for the protective effect of low-dose lithium in podocytopathy.

Am J Pathol. 184: 2742-2756Shankland S.J. Pippin J.W. Reiser J. Mundel P.

Podocytes in culture: past, present, and future.

Kidney Int. 72: 26-36Maeda M. Hayashi T. Mizuno N. Hattori Y. Kuzuya M.

Intermittent high glucose implements stress-induced senescence in human vascular endothelial cells: role of superoxide production by NADPH oxidase.

PLoS One. 10e0123169

TGF-β Signaling in Cellular Senescence and Aging-Related Pathology.

Int J Mol Sci. 20Debacq-Chainiaux F. Erusalimsky J.D. Campisi J. Toussaint O.

Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo.

Nature protocols. 4: 1798-1806Baird L. Dinkova-Kostova A.T.

The cytoprotective role of the Keap1-Nrf2 pathway.

Arch Toxicol. 85: 241-272Zhou S. Wang P. Qiao Y. Ge Y. Wang Y. Quan S. Yao R. Zhuang S. Wang L.J. Du Y. Liu Z. Gong R.

Genetic and Pharmacologic Targeting of Glycogen Synthase Kinase 3β Reinforces the Nrf2 Antioxidant Defense against Podocytopathy.

J Am Soc Nephrol. 27: 2289-2308Ju W. Greene C.S. Eichinger F. Nair V. Hodgin J.B. Bitzer M. Lee Y.S. Zhu Q. Kehata M. Li M. Jiang S. Rastaldi M.P. Cohen C.D. Troyanskaya O.G. Kretzler M.

Defining cell-type specificity at the transcriptional level in human disease.

Genome research. 23: 1862-1873Bryan H.K. Olayanju A. Goldring C.E. Park B.K.

The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation.

Biochem Pharmacol. 85: 705-717

Monocarboxylic acid transport.

Compr Physiol. 3: 1611-1643Abe Y. Sakairi T. Kajiyama H. Shrivastav S. Beeson C. Kopp J.B.

Bioenergetic characterization of mouse podocytes.

Am J Physiol Cell Physiol. 299: C464-476Forli S. Huey R. Pique M.E. Sanner M.F. Goodsell D.S. Olson A.J.

Computational protein-ligand docking and virtual drug screening with the AutoDock suite.

Nat Protoc. 11: 905-919Kim K. Cha J.S. Kim J.S. Ahn J. Ha N.C. Cho H.S.

Crystal structure of GSK3β in complex with the flavonoid, morin.

Biochemical and biophysical research communications. 504: 519-524Kramer T. Schmidt B. Lo Monte F.

Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models.

Int J Alzheimers Dis. 2012: 381029Cuenoud B. Hartweg M. Godin J.P. Croteau E. Maltais M. Castellano C.A. Carpentier A.C. Cunnane S.C.

Metabolism of Exogenous D-Beta-Hydroxybutyrate, an Energy Substrate Avidly Consumed by the Heart and Kidney.

Front Nutr. 7: 13Brosius 3rd, F.C. Alpers C.E. Bottinger E.P. Breyer M.D. Coffman T.M. Gurley S.B. Harris R.C. Kakoki M. Kretzler M. Leiter E.H. Levi M. McIndoe R.A. Sharma K. Smithies O. Susztak K. Takahashi N. Takahashi T.

Mouse models of diabetic nephropathy.

J Am Soc Nephrol. 20: 2503-2512Chakraborty S. Galla S. Cheng X. Yeo J.Y. Mell B. Singh V. Yeoh B. Saha P. Mathew A.V. Vijay-Kumar M. Joe B.

Salt-Responsive Metabolite, beta-Hydroxybutyrate, Attenuates Hypertension.

Cell Rep. 25: 677-689 e674Tomita I. Kume S. Sugahara S. Osawa N. Yamahara K. Yasuda-Yamahara M. Takeda N. Chin-Kanasaki M. Kaneko T. Mayoux E. Mark M. Yanagita M. Ogita H. Araki S.I. Maegawa H.

SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition.

Cell metabolism. 32: 404-419 e406Tobin R.B. Mehlman M.A. Kies C. Fox H.M. Soeldner J.S.

Nutritional and metabolic studies in humans with 1,3-butanediol.

Fed Proc. 34: 2171-2176Mackerer C.R. Saunders R.N. Haettinger J.R. Mehlman M.A.

Influence of 1,3-butanediol on blood glucose concentration and pancreatic insulin content of streptozotocin-diabetic rats.

Fed Proc. 34: 2191-2196Fischer T. Och U. Klawon I. Och T. Grüneberg M. Fobker M. Bordewick-Dell U. Marquardt T.

Effect of a Sodium and Calcium DL-β-Hydroxybutyrate Salt in Healthy Adults.

J Nutr Metab. 2018: 9812806Caminhotto R.O. Komino A.C.M. de Fatima Silva F. Andreotti S. Sertié R.A.L. Boltes Reis G. Lima F.B.

Oral β-hydroxybutyrate increases ketonemia, decreases visceral adipocyte volume and improves serum lipid profile in Wistar rats.

Nutr Metab (Lond). 14: 31Kumar R.R. Narasimhan M. Shanmugam G. Hong J. Devarajan A. Palaniappan S. Zhang J. Halade G.V. Darley-Usmar V.M. Hoidal J.R. Rajasekaran N.S.

Abrogation of Nrf2 impairs antioxidant signaling and promotes atrial hypertrophy in response to high-intensity exercise stress.

J Transl Med. 14: 86Camer D. Yu Y. Szabo A. Wang H. Dinh C.H. Huang X.F.

Bardoxolone methyl prevents the development and progression of cardiac and renal pathophysiologies in mice fed a high-fat diet.

Chem Biol Interact. 243: 10-18Zheng H. Whitman S.A. Wu W. Wondrak G.T. Wong P.K. Fang D. Zhang D.D.

Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy.

Diabetes. 60: 3055-3066

Role of Senescent Renal Cells in Pathophysiology of Diabetic Kidney Disease.

Current diabetes reports. 20: 33

The Signaling of Cellular Senescence in Diabetic Nephropathy.

Oxid Med Cell Longev. 2019: 7495629Han Y.M. Ramprasath T. Zou M.H.

β-hydroxybutyrate and its metabolic effects on age-associated pathology.

Exp Mol Med. 52: 548-555Yuan H. Xu Y. Luo Y. Wang N.X. Xiao J.H.

Role of Nrf2 in cell senescence regulation.

Mol Cell Biochem. 476: 247-259Shin S.H. Lee E.J. Chun J. Hyun S. Kim Y.I. Kang S.S.

The nuclear localization of glycogen synthase kinase 3beta is required its putative PY-nuclear localization sequences.

Mol Cells. 34: 375-382Salazar M. Rojo A.I. Velasco D. de Sagarra R.M. Cuadrado A.

Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2.

J Biol Chem. 281: 14841-14851Rada P. Rojo A.I. Chowdhry S. McMahon M. Hayes J.D. Cuadrado A.

SCF/-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner.

Mol Cell Biol. 31: 1121-1133

History of the ketogenic diet.

Epilepsia. 49: 3-5Ferrannini E. Baldi S. Frascerra S. Astiarraga B. Heise T. Bizzotto R. Mari A. Pieber T.R. Muscelli E.

Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.

Diabetes. 65: 1190-1195Neuen B.L. Young T. Heerspink H.J.L. Neal B. Perkovic V. Billot L. Mahaffey K.W. Charytan D.M. Wheeler D.C. Arnott C. Bompoint S. Levin A. Jardine M.J.

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.

Lancet Diabetes Endocrinol. 7: 845-854Clarke K. Tchabanenko K. Pawlosky R. Carter E. Todd King M. Musa-Veloso K. Ho M. Roberts A. Robertson J. Vanitallie T.B. Veech R.L.

Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects.

Regul Toxicol Pharmacol. 63: 401-408